Literature DB >> 9504608

Combined Epstein-Barr virus and human papillomavirus infection in nasopharyngeal carcinoma.

C H Rassekh1, P L Rady, I Arany, S K Tyring, S Knudsen, K H Calhoun, H Seikaly, B J Bailey.   

Abstract

Epstein-Barr virus (EBV) has been shown to be a likely etiologic agent in nasopharyngeal carcinogenesis. Human papillomaviruses (HPVs) have previously been identified in numerous upper aerodigestive tract carcinomas. This pilot study was undertaken to investigate the prevalence of combined EBV and HPV infection in 17 patients with nasopharyngeal carcinoma (NPCA) using polymerase chain reaction (PCR). The primary goal was to determine if the presence of HPV could be correlated with molecular, histologic, or clinical parameters. There were seven patients with undifferentiated NPCA (World Health Organization [WHO] type III) and 10 patients with squamous cell carcinoma (WHO type I). All 17 patients had stage IV disease at presentation. EBV was identified in 15 patients (88.2%), and HPV subtypes were identified in samples from nine patients (52.9%). All HPV-positive cases were also EBV positive. Western blot analysis of six samples showed a high level of expression of c-myc and cdc2 kinase and a low level of p53 protein in NPCAs that contained both HPV and EBV (n = 3). Increased expression of c-myc and cdc2 kinase was seen in the cases that contained EBV only, but to a lesser extent (n = 2). These findings indicate an effect of the virus on cellular proliferation and differentiation. Similarly, an elevated level of Rb protein was found only in the HPV-containing NPCAs. Moderate differentiation (keratinization) occurred in four of eight HPV-negative and none of the nine HPV-positive NPCAs. (All HPV-positive cases were poorly differentiated or undifferentiated.) This difference is statistically significant for this sample size (P < 0.03). There was a trend for the group that was HPV positive to have WHO III histology and for the HPV-negative group to have WHO I. The presence of HPV could not be correlated with any clinical parameters in this small group of patients with advanced disease; however, these data suggest that coexistence of EBV and HPV infection may be a factor in the pathogenesis of NPCA and may have an effect on regulation of cellular proliferation and differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9504608     DOI: 10.1097/00005537-199803000-00010

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  16 in total

Review 1.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

2.  Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations.

Authors:  Michael S McLemore; Missak Haigentz; Richard V Smith; Gerard J Nuovo; Llucia Alos; Antonio Cardesa; Margaret Brandwein-Gensler
Journal:  Head Neck Pathol       Date:  2010-03-24

3.  High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.

Authors:  Heather M Walline; Chris Komarck; Jonathan B McHugh; Serena A Byrd; Matthew E Spector; Samantha J Hauff; Martin P Graham; Emily Bellile; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Douglas B Chepeha; Francis P Worden; Matthew H Stenmark; Avraham Eisbruch; Carol R Bradford; Thomas E Carey
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-12       Impact factor: 6.223

4.  Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis.

Authors:  Ru Jiang; Oleksandr Ekshyyan; Tara Moore-Medlin; Xiaohua Rong; Sean Nathan; Xin Gu; Fleurette Abreo; Eben L Rosenthal; Mingxia Shi; Joseph T Guidry; Rona S Scott; Lindsey M Hutt-Fletcher; Cherie-Ann O Nathan
Journal:  J Oral Pathol Med       Date:  2014-07-18       Impact factor: 4.253

5.  Expression of p16 in sinonasal undifferentiated carcinoma (SNUC) without associated human papillomavirus (HPV).

Authors:  Beth Wadsworth; Jeffery M Bumpous; Alvin W Martin; Michael R Nowacki; Alfred B Jenson; Hanan Farghaly
Journal:  Head Neck Pathol       Date:  2011-07-30

6.  Human papillomavirus and WHO type I nasopharyngeal carcinoma.

Authors:  Emily J Lo; Diana Bell; Jason S Woo; Guojun Li; Ehab Y Hanna; Adel K El-Naggar; Erich M Sturgis
Journal:  Laryngoscope       Date:  2010-10       Impact factor: 3.325

7.  Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.

Authors:  Matthew H Stenmark; Jonathan B McHugh; Matthew Schipper; Heather M Walline; Christine Komarck; Felix Y Feng; Francis P Worden; Gregory T Wolf; Douglas B Chepeha; Mark E Prince; Carol R Bradford; Suresh K Mukherji; Avraham Eisbruch; Thomas E Carey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-01       Impact factor: 7.038

8.  HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans.

Authors:  Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Jonathan B McHugh; Kitrina G Cordell; Avraham Eisbruch; Francis P Worden; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jay Stoerker; Heather Walline; Thomas E Carey; Carol R Bradford
Journal:  Head Neck       Date:  2010-05       Impact factor: 3.147

9.  Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas.

Authors:  Wen Jiang; Paul D Chamberlain; Adam S Garden; Betty Y S Kim; Dominic Ma; Emily J Lo; Diana Bell; G Brandon Gunn; Clifton D Fuller; David I Rosenthal; Beth M Beadle; Steven J Frank; William H Morrison; Adel K El-Naggar; Bonnie S Glisson; Erich M Sturgis; Jack Phan
Journal:  Head Neck       Date:  2015-11-11       Impact factor: 3.147

10.  Increasing incidence of Epstein-Barr virus-related nasopharyngeal carcinoma in the United States.

Authors:  Ilona Argirion; Katie R Zarins; Julie J Ruterbusch; Patravoot Vatanasapt; Hutcha Sriplung; Erlene K Seymour; Laura S Rozek
Journal:  Cancer       Date:  2019-09-16       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.